Session: 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Poster III
Hematology Disease Topics & Pathways:
Biological, antibodies, Adult, Diseases, Therapies, Combinations, infusion, Study Population, Myeloid Malignancies, Clinically relevant
Aims: To evaluate the efficacy and safety of a fixed-volume infusion of Isa in combination with Pd in relapsed/refractory multiple myeloma (RRMM).
Methods: This open-label, multicenter, two-part, Phase 1b study (NCT02283775), enrolled RRMM patients aged ≥18 years, who had received ≥2 prior lines of therapy, including lenalidomide and a proteasome inhibitor, and who demonstrated disease progression. Part A was an Isa dose-escalation study. In Part B, Isa (10 mg/kg) was administered as a fixed infusion volume of 250 mL (mL/h infusion rate) with standard doses of Pd. The primary endpoint for Part B was the incidence of Grade ≥3 infusion reactions (IRs) during the first 6 Isa infusions (patients treated for ≥2 cycles). Secondary endpoints included duration of infusion, safety, efficacy, and immunogenicity.
Results: Of 47 patients enrolled and treated in Part B, 22 (47%) remained on treatment at data cut-off. Prior to study entry, 23 (49%) and 11 (23%) patients had received P and carfilzomib, respectively; all patients with prior P exposure were refractory to P. Seven (15%) and 9 (19%) patients, respectively, had received prior daratumumab (Dara) and elotuzumab. All patients with prior Dara exposure were refractory to Dara; none of the patients received Dara as last regimen. The overall median duration of exposure was 36.9 weeks (range 1–77) and number of cycles was 9 (median; range 1–19). IRs were reported in 19/47 (40%) patients, all Grade 2 in severity (no Grade ≥3), and occurred only during the first infusion. Median duration of the first, second and ≥3 infusions were 3.7, 1.8 and 1.2 hours, respectively. All patients experienced ≥1 treatment-emergent adverse event (TEAE). Safety data are summarized in the Table. The most common non-hematologic TEAEs were fatigue (64%), IRs (40%), cough (40%), and upper respiratory tract infection (40%); 6 patients (13%) died within 30 days of their final study treatment. The overall response rate (ORR) was 53% in all patients (56% in response evaluable population) and 60% in those without prior Dara. In 6 patients evaluable for response who had prior Dara exposure, 1 had partial response, 2 had minimal response, and 3 had stable disease. The ORR in patients with prior P treatment and those without prior P or Dara was 52% (12/23) and 56% (13/23), respectively. Median time to first response was 0.95 months (range 0.9–3.4). At a median duration of 9.9 months follow-up (range 0–17.3), median duration of response (DOR), progression free survival (PFS), and overall survival (OS) were not reached. Six- and 12-month probability of PFS were 65% (95% CI: 49–77%) and 56% (95% CI: 40–69%), respectively, and 6- and 12-month OS were 84% (95% CI: 70–92%) and 71% (95% CI: 54–82%), respectively.
Conclusions: Efficacy and safety findings observed in the current study were consistent with the data from the Isa-Pd infusion schedule reported in the pivotal Phase 3 ICARIA study. Measurements of response were robust, with the median DOR not reached. There were no Grade ≥3 IRs, and no further IRs observed after ≥2 infusions, despite the increased infusion rate and shorter infusion duration of the second and subsequent infusions. These results confirm the safety, efficacy and feasibility of Isa administered by a fixed infusion volume method.
Disclosures: Usmani: BMS, Celgene: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; Amgen: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; Merck: Consultancy, Research Funding; Incyte: Research Funding; Pharmacyclics: Research Funding; GSK: Consultancy, Research Funding; Celgene: Other; Abbvie: Consultancy; SkylineDX: Consultancy, Research Funding; Seattle Genetics: Consultancy, Research Funding; Array Biopharma: Research Funding; Janssen: Consultancy, Honoraria, Other: Speaking Fees, Research Funding; Sanofi: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Other: Speaking Fees, Research Funding. Bensinger: BMS: Consultancy, Honoraria, Research Funding, Speakers Bureau; Sanofi: Consultancy, Honoraria, Research Funding, Speakers Bureau; Janssen: Consultancy, Honoraria, Research Funding, Speakers Bureau; Amgen: Consultancy, Honoraria, Research Funding, Speakers Bureau; GSK: Consultancy, Honoraria, Research Funding, Speakers Bureau; Regeneron: Consultancy, Honoraria, Research Funding, Speakers Bureau. D'Souza: Imbrium: Honoraria; Takeda: Research Funding; Sanofi: Research Funding; Janssen: Consultancy; Pfizer: Honoraria; TeneoBio: Research Funding; Akcea: Honoraria. Raje: Janssen: Consultancy; Caribou: Membership on an entity's Board of Directors or advisory committees; Astrazeneca: Consultancy; Takeda: Consultancy; BMS: Consultancy; Amgen: Consultancy; Karyopharm: Consultancy; Celgene: Consultancy; Bluebird, Bio: Consultancy, Research Funding; Immuneel: Membership on an entity's Board of Directors or advisory committees. Tuchman: Sanofi: Honoraria, Research Funding; Roche: Research Funding; Caelum: Honoraria; Karyopharm: Honoraria, Research Funding; Celgene: Honoraria, Research Funding, Speakers Bureau; Oncopeptides: Consultancy; Janssen: Research Funding; Amgen: Research Funding. Sborov: Celgene, Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Personal fees; University of Utah: Current Employment. Kanagavel: Sanofi: Current Employment. Saleem: Sanofi: Current Employment. Dubin: Sanofi: Current Employment. Campana: Sanofi Genzyme: Current Employment. Richardson: Celgene/BMS, Oncopeptides, Takeda, Karyopharm: Research Funding.
See more of: Oral and Poster Abstracts